Evidence map›Paper›PMID 32789675›Full record

ArticleEuropean archives of psychiatry and clinical neuroscience2021

Rapastinel alleviates the neurotoxic effect induced by NMDA receptor blockade in the early postnatal mouse brain.

Andrei-Nicolae Vasilescu, Anne Mallien, Natascha Pfeiffer, Undine E Lang, Peter Gass, Dragos Inta

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of psychiatry and clinical neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Andrei-Nicolae VasilescuRG Animal Models in Psychiatry, Department of Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental Health Mannheim, Heidelberg University, J 5, 68159, Mannheim, Germany.
Anne MallienRG Animal Models in Psychiatry, Department of Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental Health Mannheim, Heidelberg University, J 5, 68159, Mannheim, Germany.
Natascha PfeifferRG Animal Models in Psychiatry, Department of Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental Health Mannheim, Heidelberg University, J 5, 68159, Mannheim, Germany.
Undine E LangDepartment of Psychiatry (UPK), University of Basel, Wilhelm Klein Str. 27, 4002, Basel, Switzerland.
Peter Gass *RG Animal Models in Psychiatry, Department of Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental Health Mannheim, Heidelberg University, J 5, 68159, Mannheim, Germany.
Dragos Inta *RG Animal Models in Psychiatry, Department of Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental Health Mannheim, Heidelberg University, J 5, 68159, Mannheim, Germany. Dragos.Inta@upk.ch.
Heidelberg University · DEUniversity of Basel · CHCentral Institute of Mental Health · DEUniversity Hospital Heidelberg · DE

Funding

Bundesministerium für Bildung und Forschung Neuron Cofund (ERA-NET NEURON NMDAR-PSY)Deutsche Forschungsgemeinschaft IN 168/3-1
6 · The paper itself

Abstract

Rapastinel is a novel psychoactive substance that acts as an N-methyl-D-aspartate-receptor (NMDAR) agonist and triggers antidepressant- and antipsychotic-like effects in animal models. However, it is unknown if rapastinel possesses a better side-effect profile than fast-acting glutamatergic antidepressants, like ketamine, which trigger neurotoxicity in the perinatal rodent cortex and protracted schizophrenia-like alterations. Here we found a remarkable neuroprotective effect of rapastinel against apoptosis induced by the NMDAR antagonist MK-801 in comparison to that elicited by clozapine and the mGlu2/3 agonist LY354740. These results suggest the potential therapeutic/prophylactic effect of rapastinel in ameliorating deleterious effects induced by NMDAR blockade during neurodevelopment.

Indexed as

Cerebral CortexNeuroprotective AgentsOligopeptidesReceptors, N-Methyl-D-AspartateAnimalsMiceGLYX-13 peptideNeuroprotective AgentsOligopeptidesReceptors, N-Methyl-D-AspartateAntipsychotic drugCaspase-3MK-801NeuroprotectionNeurotoxicityRapastinel

Identifiers

PMID32789675
OpenAlexW3049365318

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.